Lexeo Therapeutics
Gene Therapy
3 open roles Gene Therapy New York City, United States 59 employees $514M raised Est. 2017
D1 Capital Partners
Omega Funds
Eventide Asset Management
Janus Henderson Investors
Longitude Capital
PBM Capital
About Lexeo Therapeutics
Advancing gene therapy for genetic cardiovascular and neurodegenerative diseases.
Lexeo Therapeutics is listed on Rocketlist with 3 active roles. The company is categorized as Gene Therapy in BioTech. Lexeo Therapeutics is at Public stage, with a B2B business model, headquartered in New York City, United States. Lexeo Therapeutics was founded in 2017 and has 59 employees. Lexeo Therapeutics has raised $514M. Active roles are refreshed daily from public hiring sources.